Thus, the lowering of tau pathology was similar when ACY-738 was administered before or after intracerebral seeding, in keeping with the results obtained in the neuronal tau inclusion model where compound addition days after AD-tau seeding still led to reduced pathology. This evidence concerns the gene MAPT and Alzheimer disease.